Stock 001065343 EDWARDS LIFESCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Edwards Lifesciences Corporation Stock Berne S.E.

Equities

001065343

US28176E1082

Advanced Medical Equipment & Technology

Delayed Berne S.E.
Other stock markets
 12:00:02 2024-04-05 pm EDT 		5-day change 1st Jan Change
83.18 CHF +1.86% Intraday chart for Edwards Lifesciences Corporation -.--% +20.95%
Jun. 05 Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus CI
Jun. 05 Transcript : Edwards Lifesciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:30 AM

Financials

Sales 2024 * 6.56B 5.84B Sales 2025 * 7.2B 6.41B Capitalization 52.6B 46.79B
Net income 2024 * 1.61B 1.43B Net income 2025 * 1.86B 1.66B EV / Sales 2024 * 7.76 x
Net cash position 2024 * 1.67B 1.49B Net cash position 2025 * 2.8B 2.49B EV / Sales 2025 * 6.91 x
P/E ratio 2024 *
33 x
P/E ratio 2025 *
28.3 x
Employees 19,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.59%
More Fundamentals * Assessed data

Chart Edwards Lifesciences Corporation

Dynamic Chart

Latest news about Edwards Lifesciences Corporation

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus CI
Transcript : Edwards Lifesciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:30 AM
Transcript : Edwards Lifesciences Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 12:00 PM
Sector Update: Health Care Stocks Steady Premarket Monday MT
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Division for $4.2 Billion in Cash MT
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln RE
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion MT
Becton, Dickinson and Company entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. CI
Some of the biggest splits in Corporate America RE
Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 MT
Deutsche Bank Upgrades Edwards Lifesciences to Buy From Hold, Raises Price Target to $103 From $86 MT
Edwards Lifesciences Insider Sold Shares Worth $439,038, According to a Recent SEC Filing MT
Edwards Lifesciences Faces EU Antitrust Complaint By Meril MT
Edwards Lifesciences hit with Meril's EU antitrust complaint RE
Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability CI
More news

Latest transcript on Edwards Lifesciences Corporation

Logo Edwards Lifesciences Corporation
Edwards Lifesciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:30 AM
More transcripts

Analyst Recommendations on Edwards Lifesciences Corporation

Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 MT
Deutsche Bank Upgrades Edwards Lifesciences to Buy From Hold, Raises Price Target to $103 From $86 MT
Edwards Lifesciences Insider Sold Shares Worth $439,038, According to a Recent SEC Filing MT
Barclays Adjusts Edwards Lifesciences Price Target to $101 From $100 MT
Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing MT
More recommendations

Press releases Edwards Lifesciences Corporation

Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR BU
BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader PR
Edwards Lifesciences to Sell Critical Care to BD BU
Edwards Lifesciences : Charter of the Audit Committee PU
Edwards Lifesciences : First Quarter 2024 Fact Sheet PU
More press releases

News in other languages on Edwards Lifesciences Corporation

Edwards Lifesciences : Autodesk, Gamestop, Nvidia... les valeurs à suivre aujourd'hui à Wall Street -
Edwards Lifesciences : cède sa filiale soins intensifs à Becton Dickison
EE.UU. - Valores a seguir en Wall Street (actualizado)
Edwards stellt Herzklappenmodell SAPIEN 3 Ultra RESILIA mit Technologie für verbesserte Haltbarkeit in Europa vor
Edwards lance la valve SAPIEN 3 Ultra RESILIA en Europe avec une technologie pour améliorer la durabilité
More news

Quotes and Performance

1 day+1.86%
3 months+1.86%
6 months+20.95%
Current year+20.95%
More quotes

Highs and lows

Current year
61.72
Extreme 61.716
83.18
1 year
61.72
Extreme 61.716
83.18
3 years
61.72
Extreme 61.716
146.26
5 years
60.60
Extreme 60.6
181.80
10 years
24.93
Extreme 24.9333
181.80
More quotes

Managers and Directors - Edwards Lifesciences Corporation

Managers TitleAgeSince
Bernard Zovighian CEO
 Chief Executive Officer 56 14-12-31
Scott Ullem DFI
 Director of Finance/CFO 57 13-12-31
Todd Brinton CTO
 Chief Tech/Sci/R&D Officer - 19-01-31
Members of the board TitleAgeSince
Leslie Heisz BRD
 Director/Board Member 63 16-07-04
Nicholas Valeriani CHM
 Chairman 67 14-11-12
Steven Loranger BRD
 Director/Board Member 72 16-03-15
More insiders

Company Profile

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
Advanced Medical Equipment & Technology
Calendar
2024-07-24 - Q2 2024 Earnings Release (Projected)
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Edwards Lifesciences Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.29 USD
Average target price
96.24 USD
Spread / Average Target
+10.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.77% 218B
DANAHER CORPORATION Stock Danaher Corporation
+10.16% 189B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+26.21% 151B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+32.78% 113B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.98% 64.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+2.92% 49.85B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-6.60% 37.89B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
-1.07% 34.92B
RESMED, INC. Stock ResMed, Inc.
+23.08% 31.1B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. EW Stock
  4. 001065343 Stock